Abstract

The tumor suppressor gene TP53 is the most frequently mutated gene in numerous cancer types, including prostate cancer (PCa). Specifically, missense mutations in TP53 are selectively enriched in PCa, and cluster to particular “hot spots” in the p53 DNA binding domain with mutation at the R273 residue occurring most frequently. While this residue is similarly mutated to R273C-p53 or R273H-p53 in all cancer types examined, in PCa selective enrichment of R273C-p53 is observed. Importantly, examination of clinical datasets indicated that TP53 heterozygosity can either be maintained or loss of heterozygosity (LOH) occurs. Thus, to mimic tumor-associated mutant p53, R273C-p53 and R273H-p53 isogenic PCa models were developed in the presence or absence of wild-type p53. In the absence of wild-type p53, both R273C-p53 and R273H-p53 exhibited similar loss of DNA binding, transcriptional profiles, and loss of canonical tumor suppressor functions associated with wild-type p53. In the presence of wild-type p53 expression, both R273C-p53 and R273H-p53 supported canonical p53 target gene expression yet elicited distinct cistromic and transcriptional profiles when compared to each other. Moreover, heterozygous modeling of R273C-p53 or R273H-p53 expression resulted in distinct phenotypic outcomes in vitro and in vivo. Thus, mutant p53 acts in a context-dependent manner to elicit pro-tumorigenic transcriptional profiles, providing critical insight into mutant p53-mediated prostate cancer progression.

Highlights

  • The tumor suppressor p53 (TP53) is the most frequently mutated gene in numerous tumor types, including prostate cancer (PCa), a tumor type that generally exhibits a low mutational burden [1, 2]

  • Genomic analyses of large sequencing cohorts comparing metastatic versus primary disease revealed TP53 mutations were significantly enriched in metastatic disease, and this was robust in PCa [1, 2]

  • The R273C-p53 allele is selectively enriched in PCa mutants in wt-p53-null background were developed by CRISPR

Read more

Summary

Introduction

The tumor suppressor p53 (TP53) is the most frequently mutated gene in numerous tumor types, including prostate cancer (PCa), a tumor type that generally exhibits a low mutational burden [1, 2]. PCa remains the second leading cause of cancer-related death in men in the United States [3]. Defining the mechanisms that drive progression from HSPC to the currently incurable, metastatic CRPC remains critical. Mutations in TP53 have long been implicated as harboring pro-metastatic potential [9], but the functional outcomes of TP53 mutations in both HSPC and CRPC remain largely unresolved. As such, discerning the mechanisms by which mutant p53 (mut-p53) contributes to tumorigenesis and disease progression in PCa must be addressed

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call